• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定鞣花酸为蛋白激酶CK2的有效抑制剂:虚拟筛选应用的成功范例。

Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application.

作者信息

Cozza Giorgio, Bonvini Paolo, Zorzi Elisa, Poletto Giorgia, Pagano Mario A, Sarno Stefania, Donella-Deana Arianna, Zagotto Giuseppe, Rosolen Angelo, Pinna Lorenzo A, Meggio Flavio, Moro Stefano

机构信息

Molecular Modeling Section, Dipartimento di Scienze Farmaceutiche, Università di Padova, via Marzolo 5, Padua, Italy.

出版信息

J Med Chem. 2006 Apr 20;49(8):2363-6. doi: 10.1021/jm060112m.

DOI:10.1021/jm060112m
PMID:16610779
Abstract

Casein kinase 2 (CK2) is a ubiquitous, essential, and highly pleiotropic protein kinase whose abnormally high constitutive activity is suspected to underlie its pathogenic potential in neoplasia and other diseases. Using a virtual screening approach, we have identified the ellagic acid, a naturally occurring tannic acid derivative, as a novel potent CK2 inhibitor. At present, ellagic acid represents the most potent known CK2 inhibitor (K(i) = 20 nM).

摘要

酪蛋白激酶2(CK2)是一种普遍存在、不可或缺且具有高度多效性的蛋白激酶,其异常高的组成性活性被怀疑是其在肿瘤和其他疾病中致病潜力的基础。通过虚拟筛选方法,我们鉴定出了一种天然存在的单宁酸衍生物——鞣花酸,它是一种新型的强效CK2抑制剂。目前,鞣花酸是已知最有效的CK2抑制剂(抑制常数K(i)=20 nM)。

相似文献

1
Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application.鉴定鞣花酸为蛋白激酶CK2的有效抑制剂:虚拟筛选应用的成功范例。
J Med Chem. 2006 Apr 20;49(8):2363-6. doi: 10.1021/jm060112m.
2
Urolithin as a converging scaffold linking ellagic acid and coumarin analogues: design of potent protein kinase CK2 inhibitors.尿石素作为连接鞣花酸和香豆素类似物的汇聚支架:强效蛋白激酶 CK2 抑制剂的设计。
ChemMedChem. 2011 Dec 9;6(12):2273-86. doi: 10.1002/cmdc.201100338. Epub 2011 Oct 4.
3
Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure-activity relationships.香豆素作为引人注目的酪蛋白激酶2(CK2)抑制剂支架:一种阐明假定结合基序并解释构效关系的综合方法。
J Med Chem. 2008 Feb 28;51(4):752-9. doi: 10.1021/jm070909t. Epub 2008 Feb 6.
4
Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid.人CK2α与强效抑制剂鞣花酸复合物的结构解析
Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3. doi: 10.1016/j.bmcl.2009.04.076. Epub 2009 Apr 22.
5
Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.源自4,5,6,7-四溴苯并咪唑的蛋白激酶CK2抑制剂的优化
J Med Chem. 2004 Dec 2;47(25):6239-47. doi: 10.1021/jm049854a.
6
Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking.通过高通量对接发现一种强效且选择性的蛋白激酶CK2抑制剂。
J Med Chem. 2003 Jun 19;46(13):2656-62. doi: 10.1021/jm030827e.
7
Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2.3-羧基-4(1H)-喹诺酮类化合物作为人蛋白激酶CK2抑制剂的评价
J Med Chem. 2006 Nov 2;49(22):6443-50. doi: 10.1021/jm050048t.
8
Protein kinase CK2 as a druggable target.蛋白激酶CK2作为一个可成药靶点。
Mol Biosyst. 2008 Sep;4(9):889-94. doi: 10.1039/b805534c. Epub 2008 Jun 12.
9
Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.多金属氧酸盐作为蛋白激酶CK2的纳摩尔级非竞争性抑制剂的鉴定。
Chem Biol. 2008 Jul 21;15(7):683-92. doi: 10.1016/j.chembiol.2008.05.018.
10
Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.基于结构的新型强效蛋白激酶 CK2(CK2)抑制剂的设计,以苯并唑为骨架。
J Med Chem. 2012 Mar 22;55(6):2899-903. doi: 10.1021/jm2015167. Epub 2012 Mar 7.

引用本文的文献

1
Serine/Threonine Protein Kinases as Attractive Targets for Anti-Cancer Drugs-An Innovative Approach to Ligand Tuning Using Combined Quantum Chemical Calculations, Molecular Docking, Molecular Dynamic Simulations, and Network-like Similarity Graphs.丝氨酸/苏氨酸蛋白激酶作为抗癌药物的有吸引力的靶点——一种使用组合量子化学计算、分子对接、分子动力学模拟和网络相似性图谱的创新方法来调整配体。
Molecules. 2024 Jul 5;29(13):3199. doi: 10.3390/molecules29133199.
2
Enhanced inhibitory activity of compounds containing purine scaffolds compared to protein kinase CK2α considering crystalline water.考虑结晶水时,含嘌呤支架的化合物相对于蛋白激酶CK2α具有增强的抑制活性。
RSC Med Chem. 2024 Mar 12;15(4):1274-1282. doi: 10.1039/d3md00755c. eCollection 2024 Apr 24.
3
Advances in virtual screening.虚拟筛选的进展。
Drug Discov Today Technol. 2006 Winter;3(4):405-411. doi: 10.1016/j.ddtec.2006.12.002. Epub 2007 Jan 12.
4
Utilization of kinase inhibitors as novel therapeutic drug targets: A review.激酶抑制剂作为新型治疗药物靶点的利用:综述。
Oncol Res. 2023 Feb 3;30(5):221-230. doi: 10.32604/or.2022.027549. eCollection 2022.
5
Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase.鞣花酸及其代谢物作为肝丙酮酸激酶的有效和选择性别构抑制剂。
Nutrients. 2023 Jan 22;15(3):577. doi: 10.3390/nu15030577.
6
Qualitative Estimation of Protein-Ligand Complex Stability through Thermal Titration Molecular Dynamics Simulations.通过热滴定分子动力学模拟对蛋白-配体复合物稳定性进行定性估计。
J Chem Inf Model. 2022 Nov 28;62(22):5715-5728. doi: 10.1021/acs.jcim.2c00995. Epub 2022 Oct 31.
7
CK2 and protein kinases of the CK1 superfamily as targets for neurodegenerative disorders.细胞周期蛋白依赖性激酶2(CK2)和CK1超家族的蛋白激酶作为神经退行性疾病的靶点。
Front Mol Biosci. 2022 Oct 6;9:916063. doi: 10.3389/fmolb.2022.916063. eCollection 2022.
8
Chemical Genetic Validation of CSNK2 Substrates Using an Inhibitor-Resistant Mutant in Combination with Triple SILAC Quantitative Phosphoproteomics.使用抗抑制剂突变体结合三重稳定同位素标记氨基酸定量磷酸蛋白质组学对酪蛋白激酶2底物进行化学遗传学验证
Front Mol Biosci. 2022 Jun 9;9:909711. doi: 10.3389/fmolb.2022.909711. eCollection 2022.
9
Ellagic Acid: A Review on Its Natural Sources, Chemical Stability, and Therapeutic Potential.鞣花酸:关于其天然来源、化学稳定性及治疗潜力的综述
Oxid Med Cell Longev. 2022 Feb 21;2022:3848084. doi: 10.1155/2022/3848084. eCollection 2022.
10
Compounds from Natural Sources as Protein Kinase Inhibitors.天然来源的化合物作为蛋白激酶抑制剂。
Biomolecules. 2020 Nov 12;10(11):1546. doi: 10.3390/biom10111546.